Wedbush Maintains Outperform on Larimar Therapeutics, Lowers Price Target to $9
Wedbush analyst Laura Chico maintains Larimar Therapeutics (NASDAQ:LRMR) with a Outperform and lowers the price target from $11 to $9.

Last updated: 2026-11-19 08:13:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Larimar Therapeutics, Inc. (LRMR) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $3.22, with a market capitalization of $312.86M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.92 to $6.42. This page covers its latest market performance, valuation, price trends and company information.
$312.86M | |
$2.95 | |
$3.34 | |
$2.94 | |
$2.99 | |
1.30M | |
1.37M | |
-- | |
$6.42 | |
$1.92 | |
-- | |
2026-09-30 |
Larimar Therapeutics, Inc. (LRMR) last closed at $3.22 as of 2026-11-19 00:43:00, up 7.69% ($0.23) from the previous close of $2.99.
During the latest regular trading session, LRMR traded between $2.94 and $3.34, with a volume of 1.30M shares. The closing price was near the upper end and near the lower end of its 52-week range.
Over the past seven days, Larimar Therapeutics, Inc. (LRMR) moved from $2.69 to $3.22, representing a gain of 19.78% ($0.53).
The stock traded between $2.46 and $3.35 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 1.60 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 29.0%
LRMR is currently trading at $3.22, placing it 29.0% of the way from its 52-week low of $1.92 to its 52-week high of $6.42. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Its flagship product candidate, nomlabofusp, is a subcutaneously administered recombinant fusion protein designed to deliver frataxin (FXN) to the mitochondria of patients with Friedreich's ataxia (FA), a rare genetic disease characterized by insufficient production of FXN. The company also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 71 |
| Exchange | NASDAQ |
| Company Website |
Latest news related to Larimar Therapeutics, Inc. and LRMR stock.
Wedbush analyst Laura Chico maintains Larimar Therapeutics (NASDAQ:LRMR) with a Outperform and lowers the price target from $11 to $9.
Larimar Therapeutics (NASDAQ:LRMR) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(0.35) by 17.14 percent. This is a 52.46 percent increase over losses of $(0.61) per share
Eligible investors can buy real shares of Larimar Therapeutics, Inc. (LRMR) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to LRMR, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between LRMR shares and USD.
LRMR Shares to USD
1.00 LRMR shares = 3.222 USD
Calculations are estimates based on the latest available price and are for reference only.